Avidity Biosciences (RNA) | Financial Analysis & Statements
Avidity Biosciences Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
859.0K
Operating Income
-48.0M
-5,591.97%
Net Income
-48.1M
-5,595.93%
Balance Sheet Metrics
Total Assets
278.4M
Total Liabilities
71.1M
Shareholders Equity
207.3M
Debt to Equity
0.34
Cash Flow Metrics
Operating Cash Flow
-24.4M
Free Cash Flow
-20.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Avidity Biosciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 18.6M | 10.9M | 9.8M | 9.2M | 9.3M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 53.8M | 19.2M | 12.7M | 150.4M | 101.2M |
| Selling, General & Administrative | 41.7M | 4.9M | 3.5M | 37.7M | 26.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 95.4M | 24.1M | 16.2M | 188.1M | 127.4M |
| Operating Income | -76.8M | -13.2M | -6.4M | -178.9M | -118.1M |
| Operating Margin % | -412.6% | -121.3% | -65.4% | -1,939.6% | -1,265.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | 5.0M | 104.0K |
| Interest Expense | - | - | - | 0 | 0 |
| Other Non-Operating Income | -12.0K | 2.0K | 1.0K | -57.0K | -62.0K |
| Pre-tax Income | -76.8M | -13.2M | -6.4M | -174.0M | -118.0M |
| Income Tax | -142.0K | 11.9M | 0 | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -76.7M | -25.1M | -6.4M | -174.0M | -118.0M |
| Net Margin % | -411.9% | -230.5% | -65.4% | -1,886.3% | -1,265.4% |
| Key Metrics | |||||
| EBITDA | -76.5M | -13.0M | -6.2M | -177.5M | -117.4M |
| EPS (Basic) | $-4.48 | $-1.47 | $-0.37 | $-3.34 | $-5.70 |
| EPS (Diluted) | $-4.48 | $-1.47 | $-0.37 | $-3.34 | $-5.70 |
| Basic Shares Outstanding | 17114000 | 17114000 | 17114000 | 52162000 | 20714000 |
| Diluted Shares Outstanding | 17114000 | 17114000 | 17114000 | 52162000 | 20714000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Avidity Biosciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 270.0M | - | - | 340.4M | 320.4M |
| Short-term Investments | - | - | - | 270.3M | 85.1M |
| Accounts Receivable | - | 0 | 751.0K | 2.4M | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 1.3M | - | - | 12.2M | 5.6M |
| Total Current Assets | 272.8M | 483.0K | 856.0K | 622.9M | 411.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 6.6M | 7.6M | 10.0M | 16.0M | 15.6M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | 849.0K | 850.0K |
| Total Non-Current Assets | 5.5M | 6.7M | 9.4M | 15.9M | 16.4M |
| Total Assets | 278.4M | 7.2M | 10.3M | 638.8M | 427.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 4.4M | 532.0K | 498.0K | 4.6M | 2.8M |
| Short-term Debt | 3.7M | 3.8M | 3.6M | 3.1M | 1.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 41.8M | 26.8M | 33.8M | 51.9M | 29.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | 3.0M | 6.2M | 7.6M | 10.0M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 574.0K | 574.0K | - | - | - |
| Total Non-Current Liabilities | 29.3M | 41.5M | 47.1M | 8.8M | 16.5M |
| Total Liabilities | 71.1M | 68.3M | 80.9M | 60.7M | 46.2M |
| Equity | |||||
| Common Stock | 17.0K | - | - | 7.0K | 5.0K |
| Retained Earnings | - | - | - | -358.5M | -184.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 207.3M | -61.1M | -70.6M | 578.1M | 381.4M |
| Key Metrics | |||||
| Total Debt | 3.7M | 6.8M | 9.9M | 10.7M | 11.7M |
| Working Capital | 231.0M | -26.3M | -32.9M | 571.0M | 381.5M |
Balance Sheet Composition
Avidity Biosciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -49.5M | -25.1M | -6.4M | -174.0M | -118.0M |
| Depreciation & Amortization | 323.0K | 172.0K | 138.0K | 1.4M | 639.0K |
| Stock-Based Compensation | 7.7M | 3.2M | 2.5M | 27.1M | 17.1M |
| Working Capital Changes | -9.6M | -12.4M | 60.8M | 11.4M | 1.4M |
| Operating Cash Flow | -50.7M | -22.1M | 57.1M | -131.3M | -98.3M |
| Investing Activities | |||||
| Capital Expenditures | -1.4M | -266.0K | -320.0K | -2.8M | -3.7M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | -355.8M | -85.4M |
| Investment Sales | - | - | - | 168.7M | 6.6M |
| Investing Cash Flow | -1.4M | -266.0K | -320.0K | -190.0M | -82.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | 0 |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | - | - | 0 | 0 |
| Financing Cash Flow | 42.6M | 22.8M | -56.1M | 344.8M | 163.4M |
| Free Cash Flow | -42.6M | -22.8M | 56.1M | -139.1M | -98.6M |
| Net Change in Cash | -9.5M | 442.0K | 664.0K | 23.5M | -17.4M |
Cash Flow Trend
Avidity Biosciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.09
Forward P/E
-3.39
Price to Sales
11.38
PEG Ratio
-3.39
Profitability Ratios
Profit Margin
-265.88%
Operating Margin
-3,387.89%
Return on Equity
-36.99%
Return on Assets
-399.25%
Financial Health
Current Ratio
0.07
Debt to Equity
0.02
Per Share Data
EPS (TTM)
$-4.48
Book Value per Share
$-4.04
Revenue per Share
$1.20
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RNA | 214.9M | -3.09 | - | -36.99% | -265.88% | 0.02 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






